<scp>SGLT2</scp> inhibitor dapagliflozin attenuates cardiac fibrosis and inflammation by reverting the <scp>HIF</scp> ‐2α signaling pathway in arrhythmogenic cardiomyopathy-Reference-Cited by-同舟云学术

SGLT2 inhibitor dapagliflozin attenuates cardiac fibrosis and inflammation by reverting the HIF ‐2α signaling pathway in arrhythmogenic cardiomyopathy

Published:2022-06-17 Issue:7 Volume:36 Page:
ISSN:0892-6638
Container-title:The FASEB Journal
language:en
Short-container-title:The FASEB Journal

Author:

Yang Zhe¹²^ORCID,Li Tengling³,Xian Jianzhong³,Chen Jia⁴,Huang Yin³,Zhang Qin³,Lin Xiufang³,Lu Hongyun¹,Lin Yubi²^ORCID

Affiliation:

1. Department of Endocrinology and Metabolism, Zhuhai Hospital Affiliated with Jinan University (Zhuhai People's Hospital) Jinan University Zhuhai China

2. The First Dongguan Affiliated Hospital Guangdong Medical University Dongguan China

3. Guangdong Provincial Key Laboratory of Biomedical Imaging and Guangdong Provincial Engineering Research Center of Molecular Imaging, The Fifth Affiliated Hospital Sun Yat‐sen University Zhuhai China

4. The Second Department of Cardiology The Second People's Hospital of Guangdong Province Guangzhou China

Funder

Natural Science Foundation of Guangdong Province

Publisher

Wiley

Subject

Genetics,Molecular Biology,Biochemistry,Biotechnology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1096/fj.202200243R

Reference65 articles.

1. Arrhythmogenic Cardiomyopathy

2. Molecular mechanisms of arrhythmogenic cardiomyopathy